TargetMol

Sepantronium bromide

Product Code:
 
TAR-T2111
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2111-2mg2mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-25mg25mg£192.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-50mg50mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-100mg100mg£425.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2111-500mg500mg£858.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sepantronium Bromide is a small-molecule proapoptotic agent with potential antineoplastic activity.
CAS:
781661-94-7
Formula:
C20H19BrN4O3
Molecular Weight:
443.301
Pathway:
Apoptosis; Autophagy
Purity:
0.9982
SMILES:
[Br-].COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O
Target:
Survivin; Autophagy

References

1. Nakahara T, et al. Cancer Res, 2007, 67(17), 82014-8021. 2. Iwasa T, et al. Clin Cancer Res, 2008, 14(20), 6496-6504.